News

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...
Investor's Business Daily on MSN17h
Madrigal Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark
Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
InvestorsHub on MSN1d
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...
Madrigal stock jumps as patent protection for MASH treatment extended
The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...
Taiwan News1d
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...